Journal of Clinical Endocrinology & Metabolism, Vol 61, 50-55, Copyright © 1985 by Endocrine Society

ARTICLES

The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium

A Couvineau and M Laburthe

To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio- bis(succinimidyl propionate). Sodium dodecyl sulfate-polyacrylamide gel autoradiographic studies of affinity labeled membranes revealed three major bands corresponding to [125I]VIP-protein complexes of 66,000, 33,000, and 16,000 mol wt. Labeling of the 66,000 and 33,000 mol wt complexes was specific, since it was abolished by VIP, while labeling of the 16,000 mol wt complex was not. Densitometric scanning of autoradiographs indicated that labeling of the 66,000 mol wt complex was inhibited by low VIP concentrations in the 10(-10)-10(-8) M range, but was unaffected by glucagon or octa-cholecystokinin. It was also reduced by VIP-(2-28), with a potency 1/100th that of VIP, and by GTP in the concentration range of 10(-7)-10(-3) M. The 33,000 mol wt complex behaved similarly to the 66,000 mol wt complex with respect to specificity and GTP sensitivity, but differed in one major feature, its affinity for VIP. Its labeling was inhibited by native VIP concentrations in the 10(-9)-10(-7) M range. Assuming one molecule of [125I]VIP bound per molecule of protein, two proteins of 63,000 and 30,000 mol wt were identified as VIP-binding sites. The 63,000 mol wt protein had the properties expected for the VIP receptor coupled to adenylate cyclase in human colon, while the 30,000 mol wt protein was a low affinity binding site. Treatment of human colonic membranes with the sulfhydryl reducing agent dithiothreitol before [125I]VIP binding strongly reduced the labeling of the two proteins. This finding does not support the hypothesis that the low affinity 30,000 mol wt binding site may be a monomer of the high affinity binding site.

This article has been cited by other articles:

				K. Zhang, M. R. Aruva, N. Shanthly, C. A. Cardi, S. Rattan, C. Patel, C. Kim, P. A. McCue, E. Wickstrom, and M. L. Thakur PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer J. Nucl. Med., January 1, 2008; 49(1): 112 - 121. [Abstract] [Full Text] [PDF]

				M. L. Thakur, M. R. Aruva, J. Gariepy, P. Acton, S. Rattan, S. Prasad, E. Wickstrom, and A. Alavi PET Imaging of Oncogene Overexpression Using 64Cu-Vasoactive Intestinal Peptide (VIP) Analog: Comparison with 99mTc-VIP Analog J. Nucl. Med., August 1, 2004; 45(8): 1381 - 1389. [Abstract] [Full Text] [PDF]

				T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF]

				T. KENAKIN Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J, March 1, 2001; 15(3): 598 - 611. [Abstract] [Full Text] [PDF]

				I. Virgolini, M. Raderer, A. Kurtaran, P. Angelberger, S. Banyai, Q. Yang, S. Li, M. Banyai, J. Pidlich, B. Niederle, et al. Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors N. Engl. J. Med., October 27, 1994; 331(17): 1116 - 1121. [Abstract] [Full Text]

				E. Morel, I. Dublineau, F. Lebrun, and N. M. Griffiths Alterations of the VIP-stimulated cAMP pathway in rat distal colon after abdominal irradiation Am J Physiol Gastrointest Liver Physiol, May 1, 2002; 282(5): G835 - G843. [Abstract] [Full Text] [PDF]